Equities

Bioxyne Ltd

Bioxyne Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.014
  • Today's Change0.001 / 7.69%
  • Shares traded4.12m
  • 1 Year change-6.67%
  • Beta1.4402
Data delayed at least 20 minutes, as of Sep 20 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of AUD
(except for per share items)
Fiscal data as of Jun 30 2024202420232022
ASSETS
Cash And Short Term Investments1.033.850.07
Total Receivables, Net1.520.940.25
Total Inventory2.140.990.08
Prepaid expenses------
Other current assets, total0.890.260.01
Total current assets5.596.040.41
Property, plant & equipment, net0.820.090.04
Goodwill, net------
Intangibles, net0.29120
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets6.70180.45
LIABILITIES
Accounts payable2.652.620.82
Accrued expenses------
Notes payable/short-term debt--00
Current portion long-term debt/capital leases0.18----
Other current liabilities, total0.070.070
Total current liabilities2.912.690.82
Total long term debt--00
Total debt0.1800
Deferred income tax------
Minority interest(0.31)(0.13)--
Other liabilities, total0.4900
Total liabilities3.092.560.82
SHAREHOLDERS EQUITY
Common stock19180.13
Additional paid-in capital------
Retained earnings (accumulated deficit)(15)(2.41)(0.49)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity3.6115(0.36)
Total liabilities & shareholders' equity6.70180.45
Total common shares outstanding2,0471,902129
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.